BCL2 and graft versus host disease: Our previous work has shown that pre-treatment of alloSCT recipients with short-term pharmacological inhibition of BCL2 (venetoclax) in combination with RIC permits rapid donor cell engraftment in a high percentage of mice, without graft rejection or GVHD (8).